Pathophysiologically relevant in vitro tumor models for drug screening.

Area of Science:

• Oncology
• Drug Discovery
• Translational Medicine

Background:

• High clinical trial failure rates impede cancer therapy advancement.
• Current 2D cancer cell line models inadequately represent the tumor microenvironment (TME).
• This limitation impacts the efficacy of preclinical drug screening and selection.

Purpose of the Study:

• To review the potential of advanced in vitro tumor models for preclinical drug development.
• To highlight models that better recapitulate in vivo tumor complexities.
• To emphasize improved drug selection through more accurate preclinical testing.

Main Methods:

• Review of current literature on in vitro tumor models.
• Comparison of 2D cell cultures, 3D cancer cell cultures, and primary tumor-derived cell cultures.
• Analysis of the ability of different models to mimic the tumor microenvironment.

Main Results:

• 3D cancer cell cultures and primary cell cultures offer superior recapitulation of TME compared to 2D models.
• These advanced models provide a more realistic platform for evaluating drug efficacy and toxicity.
• Improved preclinical screening can lead to better candidate drug selection.

Conclusions:

• Advanced in vitro tumor models are crucial for overcoming clinical trial attrition in cancer.
• Utilizing models that mimic in vivo complexity enhances the reliability of preclinical drug screening.
• This approach promises to accelerate the development of effective cancer therapies.